Press Releases

All Releases
View Summary Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors
Jan 4, 2017
PDF 15.5 KB Add to Briefcase
View Summary Ironwood Announces New Drug Application for DUZALLO™ (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review
Jan 4, 2017
PDF 289.6 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Jan 3, 2017
PDF 12.8 KB Add to Briefcase
View Summary Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
Dec 22, 2016
PDF 343.7 KB Add to Briefcase
View Summary Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS
Dec 22, 2016
PDF 294.4 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of Adults with IBS-C
Dec 19, 2016
PDF 333.5 KB Add to Briefcase
View Summary Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data at the American College of Rheumatology 2016 Annual Meeting
Nov 13, 2016
PDF 23.5 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
Nov 10, 2016
PDF 12.6 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update
Nov 3, 2016
PDF 103.9 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference
Nov 1, 2016
PDF 12.7 KB Add to Briefcase
View Summary Ironwood Highlights Breadth of Gout Research with Presentations at the American College of Rheumatology 2016 Annual Meeting
Oct 25, 2016
PDF 26.7 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Host Third Quarter 2016 Investor Update Call
Oct 20, 2016
PDF 13.0 KB Add to Briefcase
View Summary Nine in Ten Physicians Agree Target Goal for Gout Is Imperative, Yet Half of Patients Fail to Reach It, New Survey Shows
Oct 3, 2016
PDF 17.0 KB Add to Briefcase
View Summary Ironwood Announces U.S. Availability of ZURAMPIC® (lesinurad) 200 mg Tablets for Patients with Uncontrolled Gout
Oct 3, 2016
PDF 77.6 KB Add to Briefcase
View Summary Ironwood Closes $150 Million Debt Refinancing
Sep 26, 2016
PDF 14.7 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Sep 7, 2016
PDF 12.7 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Present at Wells Fargo 2016 Healthcare Conference
Sep 1, 2016
PDF 12.6 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
Aug 4, 2016
PDF 102.0 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Host Second Quarter 2016 Investor Update Call
Jul 21, 2016
PDF 13.1 KB Add to Briefcase
View Summary Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
Jun 9, 2016
PDF 601.9 KB Add to Briefcase
Showing 21-40 of 239 Page: 1 2 3 4 5 6 ... 12  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.